Search
KIN-3248
go.drugbank.com/drugs/DB17587InvestigationalIt was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.
Human botulinum neurotoxin A/B immune globulin
go.drugbank.com/drugs/DB14115Approved[L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism. … to more serious symptoms such as respiratory arrest and flaccid paralysis.
Categories: Human Immunoglobulin GBlack cohosh
go.drugbank.com/drugs/DB13975Approvedpositive as expected. … For these reasons, there has been a trend toward using alternative therapies to relieve menopausal symptoms.[L2301] Black cohosh has been associated with serious safety concerns.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsProducts: KLİMADYNON FİLM TABLET, 30 TABLETCNDO-109
go.drugbank.com/drugs/DB17290InvestigationalCNDO-109 are CNDO-109-activated allogeneic natural killer cells.
Synonyms: CNDO-109-NK, CNDO-109-AANK CellsPoloxamer 188
go.drugbank.com/drugs/DB11333ApprovedThe use of P188 as a potential treatment in different pathological conditions, such as chronic microvascular diseases and skeletal muscle deficiencies, is under investigation [A27217]. … P188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217].
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsProducts: Shur-clens Soln 20%Deutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigational[L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsSQ-109
go.drugbank.com/drugs/DB05186InvestigationalSQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. … Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesBismuth subnitrate
go.drugbank.com/drugs/DB13209ApprovedWithdrawnBismuth subnitrate, also referred to as bismuth oxynitrate or bismuthyl nitrate, is a highly water-soluble crystalline compound that has been used as a treatment for duodenal ulcers and anti-diarrheic … The use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.
Elinzanetant
go.drugbank.com/drugs/DB18968ApprovedInvestigational[L53798] Later the same year, it was approved in the US for the same indication. [L54216] … [A274198] On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 SubstratesSynonyms: Benzamide, 3-(5-methyl-2-tbenzeneacetamide, n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-hexahydro-7-(hydroxymethyl)pyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,.alpha.,.alpha., -trimethyl-3,5-bis(trifluoromethyl)-Imidacloprid
go.drugbank.com/drugs/DB11421ExperimentalVet approvedImidacloprid is a patented chemical, Imidacloprid is manufactured by Bayer Cropscience (part of Bayer AG) and sold under trade names Kohinor, Admire, Advantage, Gaucho, Merit, Confidor, Hachikusan, Premise … It is marketed as pest control, seed treatment, an insecticide spray, termite control, flea control, and a systemic insecticide.